Table 2 Characteristics of the study population at 12 months follow-up
n = 60 | |
|---|---|
Respiratory symptoms | |
Dyspnea | |
mMRC 0 | 30 (50%) |
mMRC ≥ 1 | 30 (50%) |
Cough | 9 (15%) |
Pulmonary function tests | |
VC (L) | 3.7 (3.1–4.3) |
VC (% predicted) | 109 (95.8–120.5) |
FEV1 (L) | 3.03 (2.5–3.5) |
FEV1 (% predicted) | 106.3 (94.5–123.5) |
FEV1/VC (%) | 81 (72.2–85) |
TLC (L) | 5.99 (5.1–6.6) |
TLC (% predicted) | 93 (85.2–103.5) |
DLCOcor (ml/min/mmHg) | 23.8 (19.7–27.1) |
DLCOcor (% predicted) | 99.1 (90.5–112.9) |
KCO (ml/min/mmHg/L) | 4.4 (9.9–4.8) |
KCO (% predicted) | 103 (94.3–114.9) |
pO2 (mmHg) | 82.2 ± 9.2 |
pCO2 (mmHg) | 36.8 ± 3.9 |
Bicarbonate (mmol/L) | 23.3 ± 2.1 |
Chest computed tomography scan | |
Normal | 10 (16%) |
Reticulations | |
1–25% | 34 (57%) |
26–50% | 8 (13%) |
> 50% | 0 (0.0%) |
Ground-glass opacities | |
1–25% | 27 (45%) |
26–50% | 1 (1.7%) |
> 50% | 1 (1.7%) |
Bronchiectasis | |
1–25% | 33 (55%) |
26–50% | 2 (3.3%) |
> 50% | 0 (0.0%) |
Emphysema | |
1–25% | 5 (8.3%) |
26–50% | 3 (5.0%) |
> 50% | 3 (5.0%) |
Honeycombing | |
1–25% | 3 (5.0%) |
> 25% | 0 (0.0%) |